Australia and New Zealand Melanoma Trials Group Revenue and Competitors
Estimated Revenue & Valuation
- Australia and New Zealand Melanoma Trials Group's estimated annual revenue is currently $16M per year.
- Australia and New Zealand Melanoma Trials Group's estimated revenue per employee is $112,200
Employee Data
- Australia and New Zealand Melanoma Trials Group has 143 Employees.
Australia and New Zealand Melanoma Trials Group Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.2M | 19 | N/A | N/A | N/A |
#2 | $16M | 143 | N/A | N/A | N/A |
#3 | $8.5M | 83 | -1% | N/A | N/A |
#4 | $9.4M | 92 | 18% | N/A | N/A |
#5 | $7.9M | 77 | 8% | N/A | N/A |
#6 | $11M | 108 | 16% | N/A | N/A |
#7 | $9.4M | 92 | 10% | N/A | N/A |
#8 | $15.8M | 141 | 7% | N/A | N/A |
#9 | $16M | 143 | 7% | N/A | N/A |
#10 | $25.5M | 227 | 21% | N/A | N/A |
What Is Australia and New Zealand Melanoma Trials Group?
The Australia and New Zealand Melanoma Trials Group (ANZMTG) coordinates and conducts quality research for melanoma control. We develop and undertake melanoma studies in collaboration with researchers and health care professionals, support networks and consumers.
keywords:N/A
N/A
Total Funding
143
Number of Employees
$16M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Australia and New Zealand Melanoma Trials Group News
... 652 patients were enrolled in the ALPINE trial across Europe (60%), the United States (17%), China (14%), New Zealand and Australia (9%)...
Zealand Pharma: After a new drug launch went sideways, Zealand had to reduce ... 2 trial and terminated an agreement with the COPD Foundation in January.
Bristol is hoping to fill that gap with a group of new launches. ... emerging markets, plus Japan, Australia, New Zealand and greater China.
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $23.6M | 143 | 10% | N/A |
#2 | $20.4M | 143 | 27% | N/A |
#3 | $31.8M | 143 | N/A | N/A |
#4 | $38.5M | 143 | 7% | N/A |
#5 | $15.7M | 143 | 6% | N/A |